Intra-Cellular Therapies reported a wider loss than expected for Q4 2024 but saw a 51% increase in revenues driven by strong prescription uptake of Caplyta. The company also signed an agreement with Johnson & Johnson for an acquisition worth $14.6 billion.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay